利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.027 秒)

    Anti-Aβ oligomer humanized antibody
    1.
    发明授权
    Anti-Aβ oligomer humanized antibody 有权
    反A＆BGR 低聚物人源化抗体

    公开(公告)号：US08303954B2

    公开(公告)日：2012-11-06

    申请号：US12852581

    申请日：2010-08-09

    申请人： Tsuguo Kubota ,  Nobuyuki Suzuki

    发明人： Tsuguo Kubota ,  Nobuyuki Suzuki

    IPC分类号： A61K39/395 ,  C07K16/18

    CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/92 ,  C07K2319/00

    摘要： An anti-cognitive dysfunction agent comprising a humanized antibody which does not bind to Aβ monomers and specifically binds only to Aβ oligomers and a fragment thereof as an active ingredient, and an therapeutic antibody which can be treat Alzheimer's disease by specifically binding amyloid β protein oligomer (Aβ oligomer) which is considered to be a cause of Alzheimer's disease are required. The present invention can provide an anti-Aβ oligomer humanized antibody and a method for treating Alzheimer's disease using the humanized antibody. An agent for treating Alzheimer's disease; an agent for suppressing formation of neuritic plaque; an inhibitor of formation of Aβ amyloid fiber; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer's disease, comprising the step of administering the humanized antibody; and a method for suppressing progression of Alzheimer's disease, comprising the step of administering the humanized antibody.

    摘要翻译： 一种抗认知功能障碍剂，其包含不与Aβ结合的人源化抗体; 单体并且仅特异性结合A＆bgr; 低聚物及其片段作为活性成分，以及可以通过特异性结合淀粉样蛋白来治疗阿尔茨海默氏病的治疗性抗体; 需要被认为是阿尔茨海默氏病的原因的蛋白质寡聚物（A＆bgr;寡聚体）。 本发明可以提供抗A＆Bgr; 低聚人源化抗体和使用人源化抗体治疗阿尔茨海默病的方法。 一种治疗阿尔茨海默氏病的药物; 抑制神经炎斑块形成的药剂; A＆Bgr的形成抑制剂 淀粉样纤维; 一种预防和治疗认知功能障碍或阿尔茨海默氏病的方法，包括施用人源化抗体的步骤; 以及抑制阿尔茨海默病进展的方法，包括施用人源化抗体的步骤。

    Anti-Aβ oligomer humanized antibody
    2.
    发明授权
    Anti-Aβ oligomer humanized antibody 有权
    反A＆BGR 低聚物人源化抗体

    公开(公告)号：US08333967B2

    公开(公告)日：2012-12-18

    申请号：US12852548

    申请日：2010-08-09

    申请人： Tsuguo Kubota ,  Nobuyuki Suzuki

    发明人： Tsuguo Kubota ,  Nobuyuki Suzuki

    IPC分类号： A61K39/395 ,  C07K16/18 ,  C12P21/08

    CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/92 ,  C07K2319/00 ,  C12N5/10 ,  C12N15/09 ,  C12N15/63

    摘要： An anti-Aβ oligomer humanized antibody which does not bind to Aβ monomers and specifically binds only to Aβ oligomers; an anti-cognitive dysfunction agent, an agent for treating Alzheimer's disease, an agent for suppressing formation of neuritic plaque and an inhibitor of formation of Aβ amyloid fiber comprising the antibody as an active ingredient; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer's disease, comprising the step of administering the antibody; and a method for suppressing progression of Alzheimer's disease, comprising the step of administering the antibody.

    摘要翻译： 反A＆BGR 不结合A＆bgr的低聚物人源化抗体; 单体并且仅特异性结合A＆bgr; 低聚物; 抗认知功能障碍剂，治疗阿尔茨海默病的药剂，抑制神经炎斑块形成的药剂和A＆Bgr的形成抑制剂; 包含抗体作为活性成分的淀粉样纤维; 一种预防和治疗认知功能障碍或阿尔茨海默病的方法，包括施用该抗体的步骤; 以及抑制阿尔茨海默病进展的方法，包括施用所述抗体的步骤。

    Anti-CD4 antibody
    6.
    发明授权
    Anti-CD4 antibody 有权
    抗CD4抗体

    公开(公告)号：US08877913B2

    公开(公告)日：2014-11-04

    申请号：US13755472

    申请日：2013-01-31

    申请人： Tomoaki Nakagawa ,  Sayaka Hori ,  Rinpei Niwa ,  Tsuguo Kubota ,  Kazuhiro Masuda ,  Kazuyasu Nakamura

    发明人： Tomoaki Nakagawa ,  Sayaka Hori ,  Rinpei Niwa ,  Tsuguo Kubota ,  Kazuhiro Masuda ,  Kazuyasu Nakamura

    IPC分类号： C07H21/04

    CPC分类号： C07K16/2812 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2319/30 ,  G01N2333/70514

    摘要： An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell.The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.

    摘要翻译： 与CD4结合的抗CD4抗体具有高亲和力并具有高效应活性，例如抗体依赖性细胞毒性（ADCC活性）或补体依赖性细胞毒性（CDC活性），涉及到疾病 到CD4表达细胞。 本发明可以提供以高亲和力结合CD4细胞外区域并且也表现出高ADCC活性或高CDC活性的单克隆抗体或其抗体片段; 产生抗体的杂交瘤; 编码抗体的DNA; 含有DNA的载体; 通过引入载体可获得的转化体; 使用杂交瘤或转化体生产抗体或其抗体片段的方法; 以及使用该抗体或其抗体片段的治疗剂或使用该抗体或其抗体片段的诊断剂。

    Anti-CD27 antibody
    8.
    发明授权
    Anti-CD27 antibody 有权
    抗CD27抗体

    公开(公告)号：US09023999B2

    公开(公告)日：2015-05-05

    申请号：US12494827

    申请日：2009-06-30

    申请人： Katsuhiro Mori ,  Naoko Hiura ,  Tsuguo Kubota ,  Akiko Furuya ,  Yutaka Kanda ,  Mitsuo Satoh

    发明人： Katsuhiro Mori ,  Naoko Hiura ,  Tsuguo Kubota ,  Akiko Furuya ,  Yutaka Kanda ,  Mitsuo Satoh

    IPC分类号： C07K16/00 ,  C12P19/00 ,  G01N33/53 ,  G01N33/574 ,  C07K16/28 ,  C12R1/91 ,  G01N33/68

    CPC分类号： G01N33/57484 ,  C07K16/2878 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/734 ,  C07K2317/92 ,  C12R1/91 ,  G01N33/6863 ,  G01N2333/70578 ,  G01N2400/02 ,  G01N2800/347

    摘要： The present invention provides a monoclonal antibody which specifically recognizes CD27 containing an O-linked sugar chain to which galactose is not bound and binds to its extracellular region, or a method for using the same.The present invention can provide a monoclonal antibody or an antibody fragment thereof, which specifically recognizes a polypeptide encoded by CD27 gene containing an O-linked sugar chain to which galactose is not bound, and binds to its extracellular region; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtainable by transforming the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a diagnostic agent or a therapeutic agent comprising the antibody or the antibody fragment thereof as an active ingredient.

    摘要翻译： 本发明提供一种单克隆抗体，其特异性识别含有O-连接的糖链的CD27，其中半乳糖不结合并结合到其胞外区域，或其使用方法。 本发明可以提供一种单克隆抗体或其抗体片段，该单克隆抗体或其抗体片段特异性识别由含有O-连接的糖链的CD27基因编码的多肽，其中半乳糖未结合到其上并结合其胞外区域; 产生抗体的杂交瘤; 编码抗体的DNA; 包含DNA的载体; 通过转化载体可获得的转化体; 使用杂交瘤或转化体生产抗体或其抗体片段的方法; 以及包含该抗体或其抗体片段作为有效成分的诊断剂或治疗剂。

    Anti system ASC amino acid transporter 2 (ASCT2) antibody
    9.
    发明授权
    Anti system ASC amino acid transporter 2 (ASCT2) antibody 有权
    抗系统ASC氨基酸转运蛋白2（ASCT2）抗体

    公开(公告)号：US08501180B2

    公开(公告)日：2013-08-06

    申请号：US13008532

    申请日：2011-01-18

    申请人： Tsuguo Kubota

    发明人： Tsuguo Kubota

    IPC分类号： A61K39/395 ,  C07K16/18

    CPC分类号： C07K16/18 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/734 ,  C07K2317/76 ,  G01N33/574

    摘要： An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (ASCT2) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of system ASC amino acid transporter 2 (ASCT2) and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.

    摘要翻译： 本发明的目的是提供一种单克隆抗体，其可用于治疗或诊断与ASC系统ASC氨基酸转运蛋白2（ASCT2）有关的疾病或使用该抗体的方法。 本发明提供了特异性识别系统ASC氨基酸转运蛋白2（ASCT2）的细胞外区域的天然三维结构并结合细胞外区域或其抗体片段的单克隆抗体; 产生抗体的杂交瘤; 编码抗体的DNA; 含有DNA的载体; 通过引入载体可获得的转化体; 使用杂交瘤或转化体生产抗体或其抗体片段的方法; 以及使用该抗体或其抗体片段的治疗剂，以及使用该抗体或其抗体片段的诊断剂。